Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;34(5):e2576.
doi: 10.1002/rmv.2576.

Systematic Review of the Efficacy and Safety of RSV-Specific Monoclonal Antibodies and Antivirals in Development

Andrea T K Sevendal  1 , Siobhan Hurley  1 , Adam W Bartlett  2   3 , William Rawlinson  1   4 , Gregory J Walker  1   4
Affiliations

Systematic Review of the Efficacy and Safety of RSV-Specific Monoclonal Antibodies and Antivirals in Development

Andrea T K Sevendal et al. Rev Med Virol. 2024 Sep.

Abstract

Respiratory syncytial virus (RSV) is a leading cause of acute respiratory infection amongst all ages, causing a significant global health burden. Preventative and therapeutic options for RSV infection have long been under development, and recently, several widely-publicised vaccines targeting older adult and maternal populations have become available. Promising monoclonal antibody (mAb) and antiviral (AV) therapies are also progressing in clinical trials, with the prophylactic mAb nirsevimab recently approved for clinical use in infant populations. A systematic review on current progress in this area is lacking. We performed a systematic literature search (PubMed, Embase, Web of Science, ClinicalTrials.gov, EudraCT, ANZCTR-searched Nov 29th, 2023) to identify studies on all RSV-specific mAbs and AV therapies that has undergone human clinical trials since year 2000. Data extraction focused on outcomes related to the therapeutic efficacy and safety of the intervention on trial, and all studies were graded against the OCEBM Levels of Evidence Table. Results from 59 studies were extracted, covering efficacy and safety data on six mAbs (motavizumab, motavizumab-YTE, nirsevimab, ALX-0171, suptavumab, clesrovimab) and 12 AV therapies (ALN-RSV01, RSV604, presatovir, MDT-637, lumicitabine, IFN-α1b, rilematovir, enzaplatovir, AK0529, sisunatovir, PC786, EDP-938). Of the mAbs reviewed, nirsevimab and clesrovimab hold considerable promise. The timeline for RSV-specific AV availability is less advanced, although EDP-938 and AK0529 have reported promising phase 2 efficacy and safety data. Moving forward, passive immunisation and treatment options for RSV infection will play a significant role in reducing the health burden of RSV, complementing recent advancements in vaccine development. TRIAL REGISTRATION: PROSPERO registration: CRD42022376633.

Keywords: RSV; antiviral; monoclonal antibody; respiratory syncytial virus; systematic review; therapeutics.

PubMed Disclaimer

References

    1. Z.‐J. Li, H.‐Y. Zhang, L.‐L. Ren, et al., “Etiological and Epidemiological Features of Acute Respiratory Infections in China,” Nature Communications 12, no. 1 (2021): 5026, https://doi.org/10.1038/s41467-021-25120-6.
    1. T. Shi, A. Arnott, I. Semogas, et al., “The Etiological Role of Common Respiratory Viruses in Acute Respiratory Infections in Older Adults: A Systematic Review and Meta‐Analysis,” Journal of Infectious Diseases 222, no. Suppl_7 (2020): S563–S569, https://doi.org/10.1093/infdis/jiy662.
    1. Y. Li, X. Wang, D. M. Blau, et al., “Global, Regional, and National Disease Burden Estimates of Acute Lower Respiratory Infections Due to Respiratory Syncytial Virus in Children Younger Than 5 Years in 2019: A Systematic Analysis,” Lancet 399, no. 10340 (2022): 2047–2064, https://doi.org/10.1016/S0140-6736(22)00478-0.
    1. F. P. Havers, M. Whitaker, M. Melgar, et al., “Characteristics and Outcomes Among Adults Aged ≥60 Years Hospitalized With Laboratory‐Confirmed Respiratory Syncytial Virus—RSV‐NET, 12 States, July 2022‐June 2023,” Morbidity and mortality weekly report 72, no. 40 (2023): 1075–1082, https://doi.org/10.15585/mmwr.mm7240a1.
    1. A. R. Falsey, P. A. Hennessey, M. A. Formica, C. Cox, and E. E. Walsh, “Respiratory Syncytial Virus Infection in Elderly and High‐Risk Adults,” New England Journal of Medicine 352, no. 17 (2005): 1749–1759, https://doi.org/10.1056/NEJMoa043951.

Publication types

MeSH terms

LinkOut - more resources